Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glucagon-like Peptide-1 Metabolism in the Setting of Acute Neprilysin Inhibition
NCT03508739Phase 3Withdrawn
- Sponsor
- University of Pennsylvania
- Start
- Jun 2018
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sacubitril + valsartan in type 2 diabetes mellitus (T2DM), prediabetes, sponsored by University of Pennsylvania. Planned start Jun 2018; status: withdrawn.
02
Drugs
sacubitril + valsartan
03
Conditions
type 2 diabetes mellitus (T2DM)prediabetes
Beyond the preview
Go deeper on NCT03508739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03508739.